/RPRX
Royalty Pharma plc
RPRX • NASDAQRPRX • NASDAQ • Healthcare
$47.43-0.11%-0.05
$47.43-0.11%(-0.05)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
66Bullish
Risk
100Low Risk
Momentum
94Positive
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
100.0%▲0.0pp
Revenue after COGS
Operating
65.6%▲8.5pp
After operating expenses
Net
32.4%▼5.5pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
21.6
Price vs earnings
EV/EBITDA
15.3
Enterprise value
FCF Yield
14.9%
Cash generation
Earnings Yield
4.6%
Inverse of P/E
Capital Efficiency
9
GoAI Quality ScoreFair
ROEReturn on Equity
11.9%Fair
ROAReturn on Assets
3.9%Fair
ROICReturn on Invested Capital
8.9%Fair
Financial Health
Current RatioWeak
0.97
Short-term solvency (>1.5)
Net Debt / EBITDAHigh
5.09x
Debt repayment capacity (<3x)
Income QualityStrong
1.88
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.38B | $2.26B | $2.35B | $2.24B | $2.29B |
| Gross Profit | $2.38B | $2.26B | $2.35B | $2.24B | $2.29B |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $1.56B | $1.29B | $1.49B | $307.06M | $1.43B |
| Net Income | $770.95M | $858.98M | $1.13B | $42.83M | $619.73M |
| Net Margin | 32.4% | 37.9% | 48.2% | 1.9% | 27.1% |
| EPS | $2.33 | $1.93 | $3.41 | $0.10 | $1.49 |
Average Price Target
$49.40▲ 4.2% Upside
Past 12 Months
12 Month Forecast
Based on 50 Wall Street analysts offering 12 month price targets for Royalty Pharma plc, the average price target is $49.40, with a high forecast of $61.00 and a low forecast of $42.00. The average price target represents a 4.2% increase from the current price of $47.43.
Highest
$61.00
Average
$49.40
Lowest
$42.00
Rating Distribution
Strong Buy
0
0%
Buy
10
91%
Hold
1
9%
Sell
0
0%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
Citigroup● Maintain
Buy
2026-01-27TD Cowen● Maintain
Buy
2025-12-11Morgan Stanley● Maintain
Overweight
2025-10-10Citigroup● Maintain
Buy
2025-07-22Morgan Stanley● Maintain
Overweight
2025-07-10Citigroup● Maintain
Buy
2024-10-25Goldman Sachs● Maintain
Buy
2024-08-14Morgan Stanley● Maintain
Overweight
2024-07-11UBS▼ Downgrade
Buy→Neutral
2024-06-03B of A Securities● Maintain
Buy
2024-04-12Earnings History & Surprises
BEAT RATE
72%
Last 18 quarters
AVG SURPRISE
+6.1%
EPS vs Estimate
BEATS / MISSES
13/4
1 met exactly
LATEST EPS
$1.46
Q1 '26
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q1 '26
+13.2%
$1.46 vs $1.29
Q4 '25
+17.7%
$1.17 vs $0.99
Q3 '25
+10.7%
$1.14 vs $1.03
Q2 '25
+11.2%
$1.06 vs $0.95
Q1 '25
+16.2%
$1.15 vs $0.99
Q4 '24
+12.1%
$1.04 vs $0.93
Q3 '24
-0.5%
$0.96 vs $0.96
Q2 '24
-0.7%
$0.98 vs $0.99
Q1 '24
+13.9%
$1.15 vs $1.01
Q4 '23
-2.5%
$0.79 vs $0.81
Q3 '23
+2.4%
$0.85 vs $0.83
Q2 '23
+21.2%
$1.60 vs $1.32
No investor questions available.
Latest News
No news available